Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: Evaluation of an approach based on the in vitro substrate disappearance rate

Xenobiotica

Volumn 34, Issue 5, 2004, Pages 415-427

  Naritomi, Y ^a   Terashita, S ^a   Kagayama, A ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CHLORZOXAZONE; COUMARIN 7 HYDROXYLASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DICLOFENAC; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; GLIBENCLAMIDE; ISOENZYME; KETOCONAZOLE; LANSOPRAZOLE; MEPHENYTOIN; N 3 BENZYLNIRVANOL; PACLITAXEL; PHENACETIN O DEETHYLASE; QUINIDINE; RECOMBINANT ENZYME; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTIBODIES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GLYBURIDE; HUMANS; KETOCONAZOLE; KINETICS; MEPHENYTOIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 3142559792     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250410001685728     Document Type: Article

References (29)

1. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261-270.
2. BOOBIS, A. R., MURRAY, S., HAMPDEN, C. E. and DAVIES, D. S., 1985, Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1′-hydroxylase activities. Biochemical Pharmacology, 34, 65-71.
3. BROLY, F., LIBERSA, C., LHERMITTE, M., BECHTEL, P. and DUPUIS, B., 1989, Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. British Journal of Clinical Pharmacology, 28, 29-36.
4. CRESPI, C. L., 1995, Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Advances in Drug Research, 26, 179-235.
5. GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEM, B. I., 1994, Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 33, 1743-1752.
6. GUENGERICH, F. P., 1996, In vitro techniques for studying drug metabolism. Journal of Pharmacokinetics and Biopharmaceutics, 24, 521-533.
7. GUENGERICH, F. P., KIM, D. H. and IWASAKI, M., 1991, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168-179.
8. HEYN, H., WHITE, R. B. and STEVENS, J. C., 1996, Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metabolism and Disposition, 24, 948-954.
9. KATSUKI, H., NAKAMURA, C., ARIMORI, K., FUJIYAMA, S. and NAKANO, M., 1997, Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. European Journal of Clinical Pharmacology, 52, 391-396.
10. KOBAYASHI, K., MIMURA, N., FUJII, H., MINAMI, H., SASAKI, Y., SHIMADA, N. and CHIBA, K., 2000, Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clinical Cancer Research, 6, 3297-3303.
11. KRAUSZ, K. W., GOLDFARB, I., BUTERS, J. T. M., YANG, T. J., GONZALEZ, F. J. and GELBOIN, H. V., 2001, Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. Drug Metabolism and Disposition, 29, 1410-1423.
12. LEEMANN, T., TRANSON, C. and DAYER, P., 1993, Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Science, 52, 29-34.
13. LIN, J. H. and LU, A. H. Y., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Phrmacokinetics, 35, 361-390.
14. LU, A. Y. H., WANG, R. W. and LIN, J. H., 2003, Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metabolism and Disposition, 31, 345-350.
15. NAKAJIMA, M., NAKAMURA, S., TOKUDOME, S., SHIMADA, N., YAMAZAKI, H. and YOKOI, T., 1999, Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metabolism and Disposition, 27, 1381-1391.
16. NARITOMI, Y., TERASHITA, S., KAGAYAMA, A. and SUGIYAMA, Y., 2003, Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metabolism and Disposition, 31, 580-588.
17. NARITOMI, Y., TERASHITA, S., KIMURA, S., SUZUKI, A., KAGAYAMA, A. and SUGIYAMA, Y., 2001, Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metabolism and Disposition, 29, 1316-1324.
18. NIEMI, M., CASCORBI, I., TIMM, R., KROEMER, H. K., NEUVONEN, P. J. and KIVISTÖ K. T., 2002, Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clinical Pharmacology and Therapeutics, 72, 326-332.
19. PEARCE, R. E., RODRIGUES, A. D., GOLDSTEIN, J. A. and PARKINSON, A., 1996, Identification of the human P450 enzymes involved in lansoprazole metabolism. Journal of Pharmacology and Experimental Therapeutics, 277, 805-816.
20. PETER, R., BÖCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chemical Research in Toxicology, 3, 566-573.
21. RAHMAN, A., KORZEKWA, K. R., GROGAN, J., GONZALEZ, F. J. and HARRIS, J. W., 1994, Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Research, 54, 5543-5546.
22. SUZUKI, A., IIDA, I., HIROTA, M., AKIMOTO, M., HIGUCHI, S., SUWA, T., TANI, M., ISHIZAKI, T. and CHIBA, K., 2003, CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metabolism and Pharmacokinetics, 18, 104-113.
23. SUZUKI, A., IIDA, I., TANAKA, F., AKIMOTO, M., FUKUSHIMA, K., TANI, M., ISHIZAKI, T. and CHIBA, K., 1999, Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metabolism and Disposition, 27, 1254-1259.
24. SUZUKI, H., KNELLER, M. B., HAINING, R. L., TRAGER, W. F. and RETTIE, A. E., 2002, (+)-N-3-benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition, 30, 235-239.
25. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. and MINERS, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 IA1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401-407.
26. VAN GIERSBERGEN, P. L. M., TREIBER, A., CLOZEL, M., BODIN, F. and DINGEMANSE, J., 2002, In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clinical Pharmacology and Therapeutics, 71, 253-262.
27. WALSKY, R. L. and OBACH, R. S., 2003, Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metabolism and Disposition, 31, 343.
28. WAXMAN, D. J., ATTISANO, C., GUENGERICH, F. P. and LAPENSON, D. P., 1988, Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Archives of Biochemistry and Biophysics, 263, 424-436.
29. YUN, C. H., SHIMADA, T. and GUENGERICH, F. P., 1991, Purification and characterization of human liver microsomal cytochrome P-450 2A6. Molecular Pharmacology, 40, 679-685.